AU2017234192B2 - Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine - Google Patents

Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine Download PDF

Info

Publication number
AU2017234192B2
AU2017234192B2 AU2017234192A AU2017234192A AU2017234192B2 AU 2017234192 B2 AU2017234192 B2 AU 2017234192B2 AU 2017234192 A AU2017234192 A AU 2017234192A AU 2017234192 A AU2017234192 A AU 2017234192A AU 2017234192 B2 AU2017234192 B2 AU 2017234192B2
Authority
AU
Australia
Prior art keywords
peptide
antigen
complex
agonist
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017234192A
Other languages
English (en)
Other versions
AU2017234192A1 (en
Inventor
Elodie BELNOUE
Madiha DEROUAZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amal Therapeutics SA
Original Assignee
Amal Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/000472 external-priority patent/WO2016146261A1/en
Application filed by Amal Therapeutics SA filed Critical Amal Therapeutics SA
Publication of AU2017234192A1 publication Critical patent/AU2017234192A1/en
Application granted granted Critical
Publication of AU2017234192B2 publication Critical patent/AU2017234192B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2017234192A 2016-03-16 2017-03-14 Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine Active AU2017234192B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPCT/EP2016/000472 2016-03-16
PCT/EP2016/000472 WO2016146261A1 (en) 2015-03-16 2016-03-16 Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
EP2016070264 2016-08-26
EPPCT/EP2016/070264 2016-08-26
PCT/EP2017/056034 WO2017157964A1 (en) 2016-03-16 2017-03-14 Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine

Publications (2)

Publication Number Publication Date
AU2017234192A1 AU2017234192A1 (en) 2018-07-26
AU2017234192B2 true AU2017234192B2 (en) 2024-04-04

Family

ID=59851405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017234192A Active AU2017234192B2 (en) 2016-03-16 2017-03-14 Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine

Country Status (17)

Country Link
US (2) US20190175748A1 (enExample)
EP (1) EP3429618B1 (enExample)
JP (1) JP7189021B2 (enExample)
AU (1) AU2017234192B2 (enExample)
CA (1) CA3010779A1 (enExample)
DK (1) DK3429618T5 (enExample)
ES (1) ES2977541T3 (enExample)
FI (1) FI3429618T3 (enExample)
HR (1) HRP20240510T1 (enExample)
HU (1) HUE066998T2 (enExample)
LT (1) LT3429618T (enExample)
PL (1) PL3429618T3 (enExample)
PT (1) PT3429618T (enExample)
RS (1) RS65430B1 (enExample)
RU (2) RU2748378C2 (enExample)
SI (1) SI3429618T1 (enExample)
WO (1) WO2017157964A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
AU2018250226B2 (en) 2017-04-04 2025-04-24 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
KR20230053001A (ko) 2017-05-19 2023-04-20 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
GB201810058D0 (en) * 2018-06-19 2018-08-08 Cytovation As Combination therapy using a peptide
CN113490688B (zh) 2018-12-26 2025-07-29 希望之城公司 可活化的被掩蔽的抗ctla4结合蛋白质
EP4025204A4 (en) * 2019-09-04 2023-10-11 Axelia Oncology Pty Ltd Cancer immunotherapy
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
US20240226256A1 (en) * 2021-05-19 2024-07-11 Queen's University At Kingston Combination Therapy Tumour Cell Vaccine
CN113444687A (zh) * 2021-05-31 2021-09-28 浙江圣希澳医学科技有限公司 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法
JP2024539940A (ja) * 2021-10-26 2024-10-31 ナビキュア バイオファーマシューティカルズ リミテッド がん及び感染症に対する組み合わせ療法
CN113945723B (zh) * 2021-10-28 2024-03-12 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用
WO2023091747A1 (en) * 2021-11-22 2023-05-25 Axial Therapeutics, Inc. Modulator compounds, pharmaceutical compositions and uses thereof
JP7748538B2 (ja) 2022-02-21 2025-10-02 悦康薬業集団股分有限公司 ウイルス膜融合阻害剤を最適化する方法、および広域スペクトルの抗コロナウイルスリポペプチドとその応用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041505A1 (en) * 2012-09-13 2014-03-20 Universite De Geneve Cell penetrating peptides
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2728904B1 (fr) 1995-01-04 1997-03-14 Pasteur Institut Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
WO2002036142A2 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
GB0218821D0 (en) 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
JP2007519612A (ja) 2003-10-15 2007-07-19 イスティチュート スペリオーレ ディ サニータ 結腸直腸癌抗原
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
EP1853305B1 (en) 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
PL2183361T3 (pl) 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Innowacyjna immunoterapia przeciwko nowotworom mózgu
WO2009018500A1 (en) 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2011519834A (ja) 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
CN102123732A (zh) 2008-06-20 2011-07-13 杜克大学 用于引发免疫应答的组合物，方法及试剂盒
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR101040281B1 (ko) 2008-08-22 2011-06-10 가톨릭대학교 산학협력단 Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물
US8074880B2 (en) 2008-12-01 2011-12-13 Research In Motion Limited Method, system and mobile device employing enhanced fingerprint authentication
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
ES2576036T3 (es) 2009-03-16 2016-07-05 Mcmaster University Métodos de vacunación
CN102459324B (zh) 2009-05-27 2014-07-09 葛兰素史密丝克莱恩生物有限公司 Casb7439构建体
US8563694B2 (en) 2009-07-31 2013-10-22 Medarex, Inc. Fully human antibodies to BTLA
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
ES2655687T3 (es) * 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
US9127077B2 (en) 2009-09-23 2015-09-08 L'universite Paris Descartes Polypeptides and nucleic acids for treating ErbB2-dependent cancers
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9175048B2 (en) 2010-04-26 2015-11-03 Universite Joseph Fourier Use of peptides as transporters intended for the internalization of molecules of interest into target cells
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
BR112013002298A2 (pt) 2010-07-30 2016-05-24 Curevac Gmbh complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica.
EP2608799B1 (en) 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US9340622B2 (en) 2010-09-14 2016-05-17 Council Of Scientific & Industrial Research Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
KR101760464B1 (ko) 2010-10-13 2017-07-24 사회복지법인 삼성생명공익재단 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
MX361355B (es) 2011-01-10 2018-12-04 Cleveland Biolabs Inc Uso del agonista del receptor tipo toll para el tratamiento del cáncer.
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
US8795678B2 (en) 2011-05-13 2014-08-05 Academia Sinica TLR-2 agonists and methods of use thereof
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
MX2014005957A (es) 2011-11-16 2015-02-04 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120073A1 (en) 2012-02-09 2013-08-15 Av Therapeutics, Inc. Synthetic toll-like receptor-4 (tlr-4) agonist peptides
WO2014009209A2 (en) 2012-07-13 2014-01-16 S-Target Therapeutics Gmbh Immunoregulatory vaccine
WO2014165101A1 (en) 2013-03-13 2014-10-09 California Stem Cell, Inc. Individualized high purity colon carcinoma stem cells, methods and use of the same
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
WO2014070663A1 (en) 2012-10-29 2014-05-08 Anderson David E Compositions and methods for diagnosis and treatment of malignant gliomas
WO2015069932A1 (en) 2013-11-06 2015-05-14 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
CA2930567C (en) 2013-11-13 2023-09-26 Regents Of The University Of Minnesota Annexin ii variant compositions and methods
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
CN107109362A (zh) 2014-10-31 2017-08-29 麻省理工学院 递送生物分子至免疫细胞
AU2015346295A1 (en) 2014-11-13 2017-05-25 The Johns Hopkins University Checkpoint blockade and microsatellite instability
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
CN107709908A (zh) 2015-06-29 2018-02-16 松下知识产权经营株式会社 冷藏库
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN109312309B (zh) 2016-01-08 2024-04-02 雷普利穆内有限公司 工程化的病毒
WO2017120670A1 (en) 2016-01-11 2017-07-20 Brian Lichty Oncolytic virus and checkpoint inhibitor combination therapy
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
EP3455350A4 (en) 2016-05-09 2020-01-15 Turnstone Limited Partnership PRIMO-VACCINATION / RECALL POLYTHERAPY
PL417980A1 (pl) 2016-07-16 2018-01-29 Univ Warszawski Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu
US11052149B2 (en) 2016-09-19 2021-07-06 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
CA3090171A1 (en) 2018-02-02 2019-08-08 Novartis Ag Combination of sting agonist and il-15/il15-ra for the treatment of cancer
WO2019246450A1 (en) 2018-06-20 2019-12-26 Yale University Rig-i agonists and treatments using same
WO2020010451A1 (en) 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
BR112023001864A2 (pt) 2020-09-14 2023-03-28 Boehringer Ingelheim Int Vacina de reforço primário heteróloga
JP2023545178A (ja) 2020-10-14 2023-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041505A1 (en) * 2012-09-13 2014-03-20 Universite De Geneve Cell penetrating peptides
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DREW M. PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS. CANCER, vol. 12, no. 4, 22 March 2012 (2012-03-22), GB, pages 252 - 264, XP055339916, ISSN: 1474-175X, DOI: 10.1038/nrc3239 *

Also Published As

Publication number Publication date
LT3429618T (lt) 2024-05-10
ES2977541T3 (es) 2024-08-26
AU2017234192A1 (en) 2018-07-26
SI3429618T1 (sl) 2024-06-28
JP7189021B2 (ja) 2022-12-13
RU2769314C1 (ru) 2022-03-30
HUE066998T2 (hu) 2024-09-28
CA3010779A1 (en) 2017-09-21
DK3429618T3 (da) 2024-04-22
DK3429618T5 (da) 2024-09-16
EP3429618B1 (en) 2024-02-21
US20190175748A1 (en) 2019-06-13
HRP20240510T1 (hr) 2024-07-05
RU2748378C2 (ru) 2021-05-25
WO2017157964A1 (en) 2017-09-21
PT3429618T (pt) 2024-04-02
US20220118102A1 (en) 2022-04-21
RU2018135097A (ru) 2020-04-16
RS65430B1 (sr) 2024-05-31
RU2018135097A3 (enExample) 2020-07-30
US12214048B2 (en) 2025-02-04
PL3429618T3 (pl) 2024-07-01
EP3429618A1 (en) 2019-01-23
JP2019508444A (ja) 2019-03-28
FI3429618T3 (fi) 2024-03-15

Similar Documents

Publication Publication Date Title
AU2017234192B2 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
JP7190528B2 (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
AU2017331949B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
EA049338B1 (ru) Новый комплекс, содержащий проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)